Please welcome the updated Human Physical Immortality Roadmap. This is the first part where we look at the evolution of biotechnologies that will lead to significant lifespan extension in humans. The whole sequence of steps will yield the best result, but of course each individual step has the potential to become quite important in improving human condition, for example developing the biomarkers of aging and longevity. One of the goals of this roadmap is to clearly illustrate the feasibility of those technological advances that will save us from the debilitating diseases of old age and buy us the precious time to live our lives the way we like.
Tag Archives: biomarkers of aging
The study, conducted by a team of scientists and clinicians from JCVI and WCHN, will focus on two groups of elderly individuals aged 65 to 85 years by correlating genetics with a variety of human genomic, gut microbiome and other “omics” profiles and integrating these data with the individuals’ health record. One group will consist of healthy individuals, and the other will have individuals with a variety of diagnosed health conditions.
This study makes no sense to me, because they want to look at the differences in health between sick people and even sicker people and call the results of the study markers of healthy aging. They propose to measure the right things, but what the study planners are missing here is the fact that aging itself is a disease. Aging can’t be healthy, because the underlying biological mechanisms that are causing age-related pathologies are active also in those aged individuals, who don’t have those diseases. To give you an example – manifestation of type 2 diabetes means that the cells lost their sensitivity to insulin, however really a lot of older people, who don’t have type 2 diabetes, have impaired insulin sensitivity. These people are considered to be just old, but not sick. That’s exactly what’s wrong with perception of aging. Everyone who reached a certain age is considered to be simply old, but not ill. However this person is 100% not healthy in a biological sense, because a lot of detrimental processes have already started their poisonous actions and altered the youthful state of the organism.
In order to find the biomarkers of aging the study design should be different. The control for an individual should be the very same individual. Let me explain. We are very different in the biological sense from each other. So, to draw conclusions about a person’s aging processes, based on a given set of parameters, we have to measure those parameters several times in the beginning of the experiment to identify the baseline for the person. Then by measuring those parameters in the long run we will be able to see the changes in levels and make conclusions regarding the underlying mechanisms of aging. Also that would be the way to judge the efficacy of interventions like caloric restriction and melatonin, or rapamycin, or other drugs. Of course, the exact study design description would be more complicated, I am just pointing out the main things here. But again, the idea is not to distinguish sick people from sick people with diagnosed diseases, the idea is to identify how the sickness, i.e. aging, can be characterized.
Here’s what important – we need to change the perception of aging, so there would be no confusing terms like “healthy aging”, which is an oxymoron. It’s like “dignified poverty”, or “merciful tyrant”. Aging is not and can not be healthy. Aging is itself a disease. It is also the cause of many other maladies like Alzheimer’s and stroke, and many others. We have to stop using the term healthy aging, because it is already making us conduct poorly designed research experiments.
Claudio Franceschi – High Throughput Technologies (OMICS) as a New Tool to Identify Biomarkers of Longevity and Healthy Aging
Enjoy the plenary talk by Dr. Claudio Franceschi, PRofessor at the University of Bologna, one of the best specialists on aging of the immune system and biomarkers of aging.
Aging biomarkers are parameters that always and in all people change during aging
It is possible to evaluate and improve therapies aimed at slowing down aging using the biomarkers of aging
The value and change dynamics of aging markers provides information about the intensity of aging processes in the cells of the patient
Aging biomarkers monitoring allows not only to diagnose various diseases, but also to prevent their development
Aging already can be slowed down at the moment. There are several scientific approaches that could lead to slowing down aging and life extension. Scientists have already been able to significantly extend lifespan of model animals. It is time to apply biogerontology knowledge in clinical practice.
In order to understand if a given therapy is effective or not, first of all we have to da all the conventional clinical tests and create the electronic health passport, and after that perform measurements of the aging biomarkers listed in the table. There indicators will provide the answer if the therapy is working.
Thereafter we can look at dozens of thousands of parameters obtained using genome and transcriptome sequencing, epigenome mapping and analysis of proteome and metabolome. Altogether these data will make anti-aging therapies more precise.